GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxford BioMedica PLC (LSE:OXB) » Definitions » EV-to-FCF

Oxford BioMedica (LSE:OXB) EV-to-FCF : -8.73 (As of May. 25, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Oxford BioMedica EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Oxford BioMedica's Enterprise Value is £334.74 Mil. Oxford BioMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £-38.35 Mil. Therefore, Oxford BioMedica's EV-to-FCF for today is -8.73.

The historical rank and industry rank for Oxford BioMedica's EV-to-FCF or its related term are showing as below:

LSE:OXB' s EV-to-FCF Range Over the Past 10 Years
Min: -118.53   Med: -5.44   Max: 637.64
Current: -8.64

During the past 13 years, the highest EV-to-FCF of Oxford BioMedica was 637.64. The lowest was -118.53. And the median was -5.44.

LSE:OXB's EV-to-FCF is ranked worse than
100% of 372 companies
in the Biotechnology industry
Industry Median: 8.36 vs LSE:OXB: -8.64

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-25), Oxford BioMedica's stock price is £3.27. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.631. Therefore, Oxford BioMedica's PE Ratio for today is At Loss.


Oxford BioMedica EV-to-FCF Historical Data

The historical data trend for Oxford BioMedica's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxford BioMedica EV-to-FCF Chart

Oxford BioMedica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.57 -79.55 60.04 -14.89 -5.86

Oxford BioMedica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 60.04 - -14.89 - -5.86

Competitive Comparison of Oxford BioMedica's EV-to-FCF

For the Biotechnology subindustry, Oxford BioMedica's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxford BioMedica's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxford BioMedica's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Oxford BioMedica's EV-to-FCF falls into.



Oxford BioMedica EV-to-FCF Calculation

Oxford BioMedica's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=334.743/-38.349
=-8.73

Oxford BioMedica's current Enterprise Value is £334.74 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was £-38.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oxford BioMedica  (LSE:OXB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Oxford BioMedica's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.27/-1.631
=At Loss

Oxford BioMedica's share price for today is £3.27.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Oxford BioMedica's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was £-1.631.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Oxford BioMedica EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Oxford BioMedica's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxford BioMedica (LSE:OXB) Business Description

Traded in Other Exchanges
Address
Windrush Court, Transport Way, Oxford, GBR, OX4 6LT
Oxford BioMedica PLC is a player in the healthcare market in the United Kingdom. As a biopharmaceutical company, it focuses on the field of immunotherapy by managing a platform of technologies for designing gene-based medicines. The company's operating segments include the Platform segment consists of the revenue-generating bioprocessing and process development activities undertaken for third parties. Its Product segment consists of the clinical and preclinical development of in vivo and ex vivo gene and cell therapy products. The company derives the maximum revenue from the Platform segment. Its Platform includes LentiVector, LentiStable, TRiPSystem, SecNuc, Analytics, and others. Geographically, it generates the majority of its revenue from Europe.

Oxford BioMedica (LSE:OXB) Headlines

No Headlines